Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Nina S. McCarthy, Ciara Vangjeli, Praveen Surendran, Achim Treumann, Cathy Rooney, Emily Ho, Peter Sever, Simon Thom, Alun D. Hughes, Patricia B. Munroe, Philip Howard, Toby Johnson, Mark Caulfield, Denis C. Shields, Eoin O'Brien, Desmond J. Fitzgerald, Alice V. Stanton

Research output: Contribution to journalArticlepeer-review

5 Citations (Web of Science)

Fingerprint

Dive into the research topics of 'Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science